NABRIVA THERAPEUTICS PLC (NBRV) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:NBRV • IE000OZRGNV6

1.42 USD
0 (0%)
At close: Jul 31, 2023
1.3986 USD
-0.02 (-1.51%)
After Hours: 7/31/2023, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NBRV. NBRV was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NBRV have multiple concerns. While showing a medium growth rate, NBRV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NBRV had negative earnings in the past year.
  • NBRV had a negative operating cash flow in the past year.
NBRV Yearly Net Income VS EBIT VS OCF VS FCFNBRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • The profitability ratios for NBRV are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBRV Yearly ROA, ROE, ROICNBRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

1.3 Margins

  • NBRV's Gross Margin of 18.76% is in line compared to the rest of the industry. NBRV outperforms 50.24% of its industry peers.
  • In the last couple of years the Gross Margin of NBRV has declined.
  • The Profit Margin and Operating Margin are not available for NBRV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.92%
GM growth 5YN/A
NBRV Yearly Profit, Operating, Gross MarginsNBRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • NBRV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NBRV has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for NBRV is higher compared to a year ago.
NBRV Yearly Shares OutstandingNBRV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
NBRV Yearly Total Debt VS Total AssetsNBRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • NBRV has an Altman-Z score of -5.39. This is a bad value and indicates that NBRV is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -5.39, NBRV is not doing good in the industry: 66.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.39
ROIC/WACCN/A
WACC6.62%
NBRV Yearly LT Debt VS Equity VS FCFNBRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • NBRV has a Current Ratio of 0.85. This is a bad value and indicates that NBRV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.85, NBRV is not doing good in the industry: 90.52% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.52 indicates that NBRV may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.52, NBRV is doing worse than 93.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.52
NBRV Yearly Current Assets VS Current LiabilitesNBRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • NBRV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.40%, which is quite impressive.
  • NBRV shows a small growth in Revenue. In the last year, the Revenue has grown by 6.16%.
  • Measured over the past years, NBRV shows a very strong growth in Revenue. The Revenue has been growing by 47.33% on average per year.
EPS 1Y (TTM)20.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.93%
Revenue 1Y (TTM)6.16%
Revenue growth 3Y57.35%
Revenue growth 5Y47.33%
Sales Q2Q%-5.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.90% on average over the next years. This is a very strong growth
  • NBRV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.14% yearly.
EPS Next Y49.57%
EPS Next 2Y39.49%
EPS Next 3Y30.2%
EPS Next 5Y21.9%
Revenue Next Year89.23%
Revenue Next 2Y66.62%
Revenue Next 3Y52.98%
Revenue Next 5Y38.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NBRV Yearly Revenue VS EstimatesNBRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NBRV Yearly EPS VS EstimatesNBRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NBRV. In the last year negative earnings were reported.
  • Also next year NBRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBRV Price Earnings VS Forward Price EarningsNBRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBRV Per share dataNBRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • NBRV's earnings are expected to grow with 30.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.49%
EPS Next 3Y30.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NBRV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NABRIVA THERAPEUTICS PLC

NASDAQ:NBRV (7/31/2023, 8:00:01 PM)

After market: 1.3986 -0.02 (-1.51%)

1.42

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-10
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners88.12%
Ins Owner Change0%
Market Cap4.55M
Revenue(TTM)36.51M
Net Income(TTM)-54.07M
Analysts40
Price Target1.02 (-28.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.21%
Min Revenue beat(2)-42.32%
Max Revenue beat(2)-6.1%
Revenue beat(4)1
Avg Revenue beat(4)-14.68%
Min Revenue beat(4)-42.32%
Max Revenue beat(4)5.63%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.63
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-8.32
FCFYN/A
OCF(TTM)-8.26
OCFYN/A
SpS11.4
BVpS-1.36
TBVpS-1.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.76%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.92%
GM growth 5YN/A
F-Score3
Asset Turnover1.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.52
Altman-Z -5.39
F-Score3
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)43.48%
Cap/Depr(5y)38.11%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.93%
EPS Next Y49.57%
EPS Next 2Y39.49%
EPS Next 3Y30.2%
EPS Next 5Y21.9%
Revenue 1Y (TTM)6.16%
Revenue growth 3Y57.35%
Revenue growth 5Y47.33%
Sales Q2Q%-5.36%
Revenue Next Year89.23%
Revenue Next 2Y66.62%
Revenue Next 3Y52.98%
Revenue Next 5Y38.14%
EBIT growth 1Y-3.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.2%
OCF growth 3YN/A
OCF growth 5YN/A

NABRIVA THERAPEUTICS PLC / NBRV FAQ

What is the fundamental rating for NBRV stock?

ChartMill assigns a fundamental rating of 1 / 10 to NBRV.


Can you provide the valuation status for NABRIVA THERAPEUTICS PLC?

ChartMill assigns a valuation rating of 1 / 10 to NABRIVA THERAPEUTICS PLC (NBRV). This can be considered as Overvalued.


How profitable is NABRIVA THERAPEUTICS PLC (NBRV) stock?

NABRIVA THERAPEUTICS PLC (NBRV) has a profitability rating of 0 / 10.